Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Novo Nordisk Aims at Top Share with Levemir
December 24, 2007
- Livalo to Rise to 3rd on Statin Market
December 17, 2007
- R&D NEWS IN BRIEF
December 17, 2007
- Combined Sales of 24 Listed Companies Up 5%, Operating Profits Up 24.5%
December 17, 2007
- Subcommittee Approves Proposals for Promotion of the Use of Generics
December 17, 2007
- CMIC Stepping Up from PVC to HVC
December 17, 2007
- 33% of Pharmacists Are in Favor of New Prescription Form: Survey
December 17, 2007
- EPS Aims at \30 Bil. in Sales in 2010
December 17, 2007
- Kurabo Starts Contract HPV Genotyping Services
December 17, 2007
- JapanBridge to Select Anticancer Drug as Its First Product
December 17, 2007
- METIS Inaugurates 3rd-Phase Plan
December 17, 2007
- New Stock Exchange Market NEO to Stimulate Drug Discovery by Bioventures
December 17, 2007
- Medical Devices to Be Re-priced if They Are 1.7 Times More Expensive than Overseas
December 17, 2007
- BUSINESS NEWS IN BRIEF
December 17, 2007
- MEDICAL DEVICE NEWS IN BRIEF
December 17, 2007
- Re-Pricing Runs Counter to Innovation: Industry
December 17, 2007
- TOPICS／Number of Female MRs Increasing but Their Retention Rates Need Improvement
December 17, 2007
- Council Inaugurated to Promote Development of Vaccines
December 17, 2007
- Pediatric Drugs Adversely Affect Developing Companies
December 17, 2007
- New Rule to Exclude Members Receiving Over \3 Mil. Donations from CDFS Review Process
December 17, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…